Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-02-16 3:07 pm Sale | 2020-12-31 | 13G | AVEO Pharmaceuticals, Inc. AVEO | Cormorant Asset Management, LP | 0 0.000% | -1,350,000 (Position Closed) | Filing History |
| 2021-02-16 3:06 pm Purchase | 2020-12-31 | 13G | Forma Therapeutics Holdings, Inc. FMTX | Cormorant Asset Management, LP | 4,460,000 9.970% | 1,080,630 (+31.98%) | Filing History |
| 2021-02-16 3:04 pm Purchase | 2021-12-31 | 13G | Otonomy, Inc. OTIC | Cormorant Asset Management, LP | 2,600,000 5.390% | 100,000 (+4.00%) | Filing |
| 2021-02-16 3:03 pm Sale | 2020-12-31 | 13G | C4 Therapeutics, Inc. CCCC | Cormorant Asset Management, LP | 2,490,065 5.790% | -3 (-0.00%) | Filing History |
| 2021-02-16 3:02 pm Sale | 2020-12-31 | 13G | Agenus Inc. AGEN | Cormorant Asset Management, LP | 356,650 3.700% | -229,275 (-39.13%) | Filing History |
| 2021-02-16 3:01 pm Sale | 2020-12-31 | 13G | ChemoCentryx, Inc. CCXI | Cormorant Asset Management, LP | 1,200,000 1.700% | -2,186,208 (-64.56%) | Filing History |
| 2021-02-16 3:00 pm Sale | 2020-12-31 | 13G | Revolution Medicines, Inc. RVMD | Cormorant Asset Management, LP | 2,495,066 3.800% | -750,111 (-23.11%) | Filing History |
| 2021-01-19 4:18 pm Purchase | 2021-01-07 | 13G | MIRAGEN THERAPEUTICS INC MGEN | Cormorant Asset Management, LP | 459,144 9.990% | 459,144 (New Position) | Filing History |
| 2021-01-04 4:01 pm Purchase | 2020-12-22 | 13G | NOVUS THERAPEUTICS INC NVUS | Cormorant Asset Management, LP | 1,415,500 9.890% | 1,415,500 (New Position) | Filing History |
| 2020-12-28 4:01 pm Purchase | 2020-12-18 | 13G | BioAtla, Inc. BCAB | Cormorant Asset Management, LP | 2,292,060 7.120% | 2,292,060 (New Position) | Filing History |
| 2020-11-23 4:59 pm Purchase | 2020-11-23 | 13G | Olema Pharmaceuticals, Inc. OLMA | Cormorant Asset Management, LP | 3,270,544 8.140% | 3,270,544 (New Position) | Filing History |
| 2020-11-13 4:01 pm Purchase | 2020-11-03 | 13G | Atea Pharmaceuticals, Inc. AVIR | Cormorant Asset Management, LP | 6,886,355 8.340% | 6,886,355 (New Position) | Filing History |
| 2020-11-12 4:22 pm Purchase | 2020-11-02 | 13G | Galecto, Inc. GLTO | Cormorant Asset Management, LP | 91,249 9.280% | 91,249 (New Position) | Filing History |
| 2020-10-30 4:00 pm Purchase | 2020-10-20 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Cormorant Asset Management, LP | 1,964,268 9.780% | 1,964,268 (New Position) | Filing History |
| 2020-10-16 4:00 pm Purchase | 2020-10-06 | 13G | C4 Therapeutics, Inc. CCCC | Cormorant Asset Management, LP | 2,490,068 5.790% | 2,490,068 (New Position) | Filing History |